KHEIR, Alaa et al. Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab. Acta Oncologica, [S. l.], v. 64, p. 1355–1364, 2025. DOI: 10.2340/1651-226X.2025.44533. Disponível em: https://medicaljournalssweden.se/actaoncologica/article/view/44533. Acesso em: 30 may. 2026.